Loading…
SeaStar Medical Holding Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ICU.
▼ -99.9% over 5Y.
today you would have $1.36▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $2.40 | $19.40 | $110.75 | $1,025.00 | $2,510.00 | |
| P/S | — | 7.8x | 125.3x | — | — | — |
| P/B | — | 0.9x | — | — | — | — |
| EPS | -$5.86 | -$66.30 | -$302.60 | -$370.00 | -$157.50 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HSCSHeartSciences Inc. | $3.03 | — | 42.7x | — | -4239.91% | $13.65M |
| GTBPGT Biopharma, Inc. | $0.30 | 0.1x | 3.8x | — | -113.52% | $13.53M |
| INTSIntensity Therapeutics Inc | $4.25 | — | 1.4x | — | -195.88% | $13.88M |
| KALAKALA BIO, Inc. | $0.69 |
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Company description provided by Yahoo Finance.
| Profit margin | — | -984.60% | -18392.59% | — | — | — |
| ROE | — | -116.65% | — | — | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.5x |
| — |
| -345.32% |
| $13.35M |
| RGNTRegentis Biomaterials Ltd | $2.00 | — | 2.2x | — | — | $14.05M |
| PHIOPhio Pharmaceuticals Corp. | $1.13 | — | 1.0x | — | -113.71% | $13.13M |